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Abstract
C24H16Br2FN3S, monoclinic, P21/n (no. 14), a = 14.9517(9) Å,
b = 5.4857(3) Å, c = 27.9582(17) Å, β = 102.434(6)°,
V = 2239.4(2) Å3, Z = 4, Rgt(F ) = 0.0444, wRref(F
2) = 0.1237,
T = 296 K.
CCDC no.: 2049426
The molecular structure is shown in the Figure. Table 1
contains crystallographic data and Table 2 contains
the list of the atoms including atomic coordinates and
displacement parameters.
Table : Data collection and handling.
Crystal: Colourless needle
Size: . × . × . mm
Wavelength: Mo Kα radiation (. Å)
μ: . mm−
Diffractometer, scan mode: SuperNova, ω
θmax, completeness: .°, >%
N(hkl)measured, N(hkl)unique, Rint: , , .
Criterion for Iobs, N(hkl)gt: Iobs >  σ(Iobs), 
N(param)refined: 
Programs: CrysAlisPRO [], SHELX [,],WinGX/
ORTEP []
Table : Fractional atomic coordinates and isotropic or equivalent
isotropic displacement parameters (Å).
Atom x y z Uiso*/Ueq
C −. () . () . () . ()
C −. () . () . () . ()
H −. −. . .*
C −. () . () . () . ()
H −. . . .*
C −. () . () . () . ()
C −. () . () . () . ()
H −. . . .*
C −. () . () . () . ()
H −. . . .*
C −. () . () . () . ()
C −. () . () . () . ()
H −. . . .*
C −. () . () . () . ()
C −. () . () . () . ()
H −. −. . .*
C −. () . () . () . ()
HA −. −. . .*
HB −. . . .*
C −. () . () . () . ()
C −. () . () . () . ()
C −. () . () . () . ()
H −. . . .*
C −. () . () . () . ()
H −. . . .*
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1H-pyrazole-1-carbothioamide (0.77 g, 2.0 mmol) and
2-bromo-1-(4-bromophenyl)ethanone (0.56 g, 2.0 mmol) in
anhydrous ethanol (10 mL) was stirred under reflux for 3 h.
The solid obtained on cooling was filtered, washed with
cold ethanol, dried, and recrystallized from dime-
thylformamide to give colourless crystals (86%yield) of the
title compound.
Experimental details
All hydrogen atoms were identified in difference Fourier
syntheses. Themethine, methylene and hydrogens bonded
to sp2 C atoms were idealized during refinement using op-
tions AFIX 13, AFIX 23 and AFIX 43, respectively in the
SHELXL-2018 program [3]. The Uiso values of the hydrogen
atoms were set to 1.2Ueq(C).
Comment
Heterocyclic compounds containing both pyrazole and
thiazolemoietieshavemanypharmacologicalandmedicinal
applications [5–10]. The syntheses of thiazolyl-pyrazolines
are of general interest. They are biologically active and act
as antibacterial [11], antifungal [12], and antioxidant [13]
agents. The X-ray crystal structures of related compounds
have been reported [14–17].
The asymmetric unit of the title structure consists of
one molecule. The molecule comprises bromophenyl
(A [C1–C6, Br1], D [C19–C24, Br2]), thiazolyl (B [C7–C9, N1,
S1]), pyrazolyl (C [C10–C12, N2, N3]) and fluorophenyl
(E[C13–C18, F1]) ring systems. In the molecule, A, B, C
and D are almost coplanar with twist angles: A/B = 8.9(2)°,
B/C = 11.4(3)° and C/D = 4.0(3)°. The fluorophenyl ring is
almost perpendicular to the ABCD plane with a C/E twist
angle of 86.07(13)°.
In the crystal, a weak intermolecular C–Br⋯F–C inter-
action is observed with geometry: Br2⋯F1 = 3.26(2) Å,
Br2⋯F1–C16 = 111.5(9)°. In addition, the planar ABCD
segments are oriented in an edge-to-face manner to
neighbouring molecules related by the 21 screw axis par-
allel to the b axis with an angle between the least-squares
planes through the ABCD segments of 71.8°.
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Table : (continued)
Atom x y z Uiso*/Ueq
C −. () . () . () . ()
C −. () . () . () . ()
H −. . . .*
C −. () . () . () . ()
H −. −. . .*
C −. () . () . () . ()
C −. () . () . () . ()
H −. . . .*
C −. () . () . () . ()
H −. . . .*
C −. () . () . () . ()
C −. () . () . () . ()
H −. . . .*
C −. () . () . () . ()
H −. −. . .*
N −. () . () . () . ()
N −. () . () . () . ()
N −. () . () . () . ()
S −. () . () . () . ()
Br −. () . () . () . ()
Br . () . () . () . ()
F −. () . () . () . ()
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